Literature DB >> 16258255

Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis.

Galina I Belova1, Oleg N Demidov, Albert J Fornace, Dmitry V Bulavin.   

Abstract

Wip1 is an amplified oncogene whose deletion causes a tumor resistant phenotype in mice. These observations provide justification for a search for Wip1 chemical inhibitors as potential anticancer drugs. Here we report a group of Wip1 inhibitors with anticancer properties both in vitro and in vivo. In vitro, inactivation of Wip1 reduces the proliferation rate of breast cancer cell lines and enhances growth inhibition caused by doxorubicin. In vivo, administration of Wip1 inhibitors decreases proliferation of xenograph tumors and tumors developed in MMTV-c-Neu transgenic mice. We propose that these agents may serve as lead compounds for the development of anticancer drugs targeting Wip1 phosphatase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258255     DOI: 10.4161/cbt.4.10.2204

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  32 in total

1.  Wip1 directly dephosphorylates gamma-H2AX and attenuates the DNA damage response.

Authors:  Hyukjin Cha; Julie M Lowe; Henghong Li; Ji-Seon Lee; Galina I Belova; Dmitry V Bulavin; Albert J Fornace
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

2.  Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.

Authors:  Anastasia R Goloudina; Kan Tanoue; Arlette Hammann; Eric Fourmaux; Xavier Le Guezennec; Dmitry V Bulavin; Sharlyn J Mazur; Ettore Appella; Carmen Garrido; Oleg N Demidov
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

3.  A small molecular scaffold for selective inhibition of Wip1 phosphatase.

Authors:  Jeong Bang; Hiroshi Yamaguchi; Stewart R Durell; Ettore Appella; Daniel H Appella
Journal:  ChemMedChem       Date:  2008-02       Impact factor: 3.466

Review 4.  Targeting protein serine/threonine phosphatases for drug development.

Authors:  Jamie L McConnell; Brian E Wadzinski
Journal:  Mol Pharmacol       Date:  2009-03-19       Impact factor: 4.436

5.  LZAP is a novel Wip1 binding partner and positive regulator of its phosphatase activity in vitro.

Authors:  J Jacob Wamsley; Natalia Issaeva; Hanbing An; Xinyuan Lu; Lawrence A Donehower; Wendell G Yarbrough
Journal:  Cell Cycle       Date:  2016-12-27       Impact factor: 4.534

Review 6.  ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease.

Authors:  Maria Soledad Sosa; Alvaro Avivar-Valderas; Paloma Bragado; Huei-Chi Wen; Julio A Aguirre-Ghiso
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

7.  Nuclear factor-kappaB (NF-kappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase.

Authors:  Julie M Lowe; Hyukjin Cha; Qian Yang; Albert J Fornace
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

Review 8.  Negative regulation of multifunctional Ca2+/calmodulin-dependent protein kinases: physiological and pharmacological significance of protein phosphatases.

Authors:  A Ishida; N Sueyoshi; Y Shigeri; I Kameshita
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

9.  WIP1 regulates the proliferation and invasion of nasopharyngeal carcinoma in vitro.

Authors:  Yongquan Zhang; Hong Sun; Guangxiang He; An Liu; Fengjun Wang; Lu Wang
Journal:  Tumour Biol       Date:  2014-05-07

10.  RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

Authors:  Joshua A Bauer; Fei Ye; Clayton B Marshall; Brian D Lehmann; Christopher S Pendleton; Yu Shyr; Carlos L Arteaga; Jennifer A Pietenpol
Journal:  Breast Cancer Res       Date:  2010-06-24       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.